metformin has been researched along with Acute Myelogenous Leukemia in 10 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin has been demonstrated to induce apoptosis in cancer cells." | 1.91 | Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress-CHOP pathway. ( Chen, J; Du, J; Hua, L; Huang, K; Jiang, X; Lai, J; Li, Y; Liu, F; Yang, N; Yu, Z; Zeng, H, 2023) |
| "Interaction between stromal cells and acute myeloid leukemia (AML) cells in bone marrow (BM) is known to contribute importantly to chemoresistance and disease recurrence." | 1.72 | Metformin sensitizes AML cells to chemotherapy through blocking mitochondrial transfer from stromal cells to AML cells. ( Chen, L; Chen, P; Hou, D; Huang, H; Li, D; Lin, X; Wang, B; Wang, X; You, R; Zhang, B; Zheng, X, 2022) |
| "Treatment of acute myeloid leukemia (AML) is still a challenge because of common relapses or resistance to treatment." | 1.51 | Oxidative phosphorylation inhibition induces anticancerous changes in therapy-resistant-acute myeloid leukemia patient cells. ( Borutinskaitė, V; Griškevičius, L; Janulis, V; Kaupinis, A; Navakauskienė, R; Valius, M; Vitkevičienė, A; Žučenka, A, 2019) |
| "Metformin treatment alone resulted in significant suppression of ROS and mitochondrial respiration with increased glycolysis accompanied by modest cytotoxicity (10-25%)." | 1.43 | Synergistic cell death in FLT3-ITD positive acute myeloid leukemia by combined treatment with metformin and 6-benzylthioinosine. ( Bradley, HL; Bunting, KD; Qu, CK; Sabnis, HS; Tripathi, S; Tse, W; Yu, WM, 2016) |
| "Finding an effective treatment for acute myeloid leukemia (AML) remains a challenge, and all cellular processes that are deregulated in AML cells should be considered in the design of targeted therapies." | 1.36 | The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. ( Arnoult, C; Bardet, V; Bouscary, D; Boyer, O; Chapuis, N; Dreyfus, F; Foretz, M; Green, AS; Hermine, O; Ifrah, N; Lacombe, C; Lambert, M; Maciel, TT; Mayeux, P; Moura, IC; Park, S; Tamburini, J; Viollet, B; Willems, L, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| You, R | 1 |
| Wang, B | 1 |
| Chen, P | 1 |
| Zheng, X | 1 |
| Hou, D | 1 |
| Wang, X | 1 |
| Zhang, B | 1 |
| Chen, L | 1 |
| Li, D | 1 |
| Lin, X | 1 |
| Huang, H | 1 |
| Hua, L | 1 |
| Yang, N | 1 |
| Li, Y | 1 |
| Huang, K | 1 |
| Jiang, X | 1 |
| Liu, F | 1 |
| Yu, Z | 1 |
| Chen, J | 1 |
| Lai, J | 1 |
| Du, J | 1 |
| Zeng, H | 1 |
| Ottone, T | 1 |
| Silvestrini, G | 1 |
| Piazza, R | 1 |
| Travaglini, S | 1 |
| Gurnari, C | 1 |
| Marchesi, F | 1 |
| Nardozza, AM | 1 |
| Fabiani, E | 1 |
| Attardi, E | 1 |
| Guarnera, L | 1 |
| Divona, M | 1 |
| Ricci, P | 1 |
| Irno Consalvo, MA | 1 |
| Ienzi, S | 1 |
| Arcese, R | 1 |
| Biagi, A | 1 |
| Fiori, L | 1 |
| Novello, M | 1 |
| Mauriello, A | 1 |
| Venditti, A | 1 |
| Anemona, L | 1 |
| Voso, MT | 1 |
| Yuan, F | 1 |
| Cheng, C | 1 |
| Xiao, F | 1 |
| Liu, H | 1 |
| Cao, S | 1 |
| Zhou, G | 1 |
| Visnjic, D | 1 |
| Dembitz, V | 1 |
| Lalic, H | 1 |
| Vitkevičienė, A | 1 |
| Janulis, V | 1 |
| Žučenka, A | 1 |
| Borutinskaitė, V | 1 |
| Kaupinis, A | 1 |
| Valius, M | 1 |
| Griškevičius, L | 1 |
| Navakauskienė, R | 1 |
| Kawashima, I | 1 |
| Mitsumori, T | 1 |
| Nozaki, Y | 1 |
| Yamamoto, T | 1 |
| Shobu-Sueki, Y | 1 |
| Nakajima, K | 1 |
| Kirito, K | 1 |
| Wang, F | 1 |
| Liu, Z | 1 |
| Zeng, J | 1 |
| Zhu, H | 1 |
| Li, J | 1 |
| Cheng, X | 1 |
| Jiang, T | 1 |
| Zhang, L | 1 |
| Zhang, C | 1 |
| Chen, T | 1 |
| Liu, T | 1 |
| Jia, Y | 1 |
| Sabnis, HS | 1 |
| Bradley, HL | 1 |
| Tripathi, S | 1 |
| Yu, WM | 1 |
| Tse, W | 1 |
| Qu, CK | 1 |
| Bunting, KD | 1 |
| Green, AS | 1 |
| Chapuis, N | 1 |
| Maciel, TT | 1 |
| Willems, L | 1 |
| Lambert, M | 1 |
| Arnoult, C | 1 |
| Boyer, O | 1 |
| Bardet, V | 1 |
| Park, S | 1 |
| Foretz, M | 1 |
| Viollet, B | 1 |
| Ifrah, N | 1 |
| Dreyfus, F | 1 |
| Hermine, O | 1 |
| Moura, IC | 1 |
| Lacombe, C | 1 |
| Mayeux, P | 1 |
| Bouscary, D | 1 |
| Tamburini, J | 1 |
1 review available for metformin and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
The Role of AMPK/mTOR Modulators in the Therapy of Acute Myeloid Leukemia.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Clinical Trials as Topic; Humans; Leukemi | 2019 |
9 other studies available for metformin and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Metformin sensitizes AML cells to chemotherapy through blocking mitochondrial transfer from stromal cells to AML cells.
Topics: Animals; Cytarabine; Diabetes Mellitus, Type 2; Humans; Leukemia, Myeloid, Acute; Metformin; Mice; M | 2022 |
Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress-CHOP pathway.
Topics: Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Endoplasmic Reticulum Stress; | 2023 |
Expression profiling of extramedullary acute myeloid leukemia suggests involvement of epithelial-mesenchymal transition pathways.
Topics: Cell Line, Tumor; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; | 2023 |
Inhibition of mTORC1/P70S6K pathway by Metformin synergistically sensitizes Acute Myeloid Leukemia to Ara-C.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytarabine; Drug Synergism; Humans; Leuk | 2020 |
Oxidative phosphorylation inhibition induces anticancerous changes in therapy-resistant-acute myeloid leukemia patient cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulati | 2019 |
Negative regulation of the LKB1/AMPK pathway by ERK in human acute myeloid leukemia cells.
Topics: Adult; Aged; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Antineoplastic Age | 2015 |
Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosi | 2015 |
Synergistic cell death in FLT3-ITD positive acute myeloid leukemia by combined treatment with metformin and 6-benzylthioinosine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Drug Synergism; Fetal | 2016 |
The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinase Kinases; Animals; Biocatalysis; C | 2010 |